Clinical trial
Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus…
NCT00391118 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00391118 |
|---|---|
| Title | Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") |
| Official title | A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatment in Advanced Ovarian Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasm |
| Intervention type | Drug |
| Interventions | enzastaurin, carboplatin, paclitaxel, placebo |
| Enrollment | 153 |
| Start date | Nov 1, 2006 |
| Primary completion | Apr 1, 2010 |
| Completion | Jul 1, 2012 |
| First posted | Oct 23, 2006 |
| Last update posted | Oct 19, 2020 |
| Countries | Belgium, Germany, Poland, Russia, Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: